Efficacy of Oral Ketamine Combined with Psychotherapy for Treatment Resistant Depression



Abstract Views
2274

Downloads
902

Citations

Share

##plugins.themes.bootstrap3.article.sidebar##

Submitted Jul 14, 2021
Published Aug 5, 2021
10.24018/ejmed.2021.3.4.979

Abstract viewed = 2274 times

Table of Contents

##plugins.themes.bootstrap3.article.main##

Background: Treatment resistant depression (TRD) is defined as a major depressive episode that does not improve in response to at least two trials, each of a different class, of antidepressant medication. Pharmacotherapy of TRD with low dose ketamines has been shown as relatively successful in recent studies. Effects of such pharmacotherapy can be augmented by combining ketamine with psychotherapeutic interventions such as Zdyb’s Therapeutic Reset of Internal Processes (TRIP) protocol.

Method: 10 adult TRD patients (4 men, 6 women) were treated with low dose ketamines and were also receiving psychotherapeutic intervention as per TRIP protocol. All patients were administered the Patient Health Questionnaire, module 9 (PHQ9) which is a measure of a major depressive episode. The PHQ9 was administered twice: on baseline (i.e., prior to treatment) and after the treatment.

Results: On average, our patients fell in the moderate range of severity with respect to symptoms of TRD at baseline (pre-TRIP) as by their mean PHQ9 score of 17.9, (SD = 5.1). Their mean PHQ9 score decreased post TRIP treatment to 9.5 (SD = 6.6): the difference is significant in a t-test, t(10) = 4.3172, p = 0002 (two-tailed). The magnitude of the decrease amounts to 46.9% of the average baseline score.

Discussion and Conclusions: Our patients experienced significant reductions in symptoms of TRD in this pilot study. Research studies are now needed with control groups of TRD patients on a waiting list or also of those receiving only the ketamine pharmacotherapy. 

Keywords: ketamine, psychotherapy, treatment resistant depression, TRIP protocol

Downloads

Download data is not yet available.

References

  1. Kessler RC and Bromet EJ. The epidemiology of depression across cultures. Annual Review of Public Health. 2013; 34: 119-138. doi: 10.1146/annurev-publhealth-031912-114409.
     Google Scholar
  2. Fava M, Davidson KG. Definition and epidemiology of treatment-resistant depression. The Psychiatric Clinics of North America. 1996;19(2):179-200. doi: 10.1016/s0193-953x(05)70283-5.
     Google Scholar
  3. Hart M. and Cernovsky Z. Ketamines for Treatment Resistant Depression in Patients with Chronic Pain and Opioid Use. Archives of Psychiatry and Behavioral Sciences. 2019;2(2):40-42.
     Google Scholar
  4. RyanWC, Marta CJ, Koek RJ. Ketamine and depression: A review. International Journal of Transpersonal Studies. 2014;33(2): 40-72.
     Google Scholar
  5. Dore J, Turnipseed B, Dwyer S, Turnipseed A, Andries J, Ascani G, Monnette C, Huidekoper A, Strauss N, Wolfson, P. Ketamine assisted psychotherapy (KAP): Patient demographics, clinical data and outcomes in three large practices administering ketamine with psychotherapy, Journal of Psychoactive Drugs. 2019;51(2):189-198.
     Google Scholar
  6. Wallach J. Pharmacokinetics and pharmacodynamics of ketamine and related compounds. Paper Presented at the Kriya Conference, The Nueva School. Hillsborough, CA, November 2, 2018.
     Google Scholar
  7. Greenway KT, Garel N, Jerome L, Feduccia A. Integrating psychotherapy and psychopharmacology: Psychedelic-assisted psychotherapy and other combined treatments. Expert Review of Clinical Pharmacology. 2020;13(6):655-670. https://doi.org/10.1080/17512433.2020.1772054.
     Google Scholar
  8. Bennett R. Paradigms of ketamine treatment. MAPS Bulletin. 2019;29(1):48-49.
     Google Scholar
  9. Rosenblat JD, Carvalho AF, Li M, Lee Y, Subramanieapillai M, McIntyre RS. Oral Ketamine for Depression: A Systematic Review. Journal of Clinical Psychiatry. 2019;80(3):18r12475. doi: 10.4088/JCP.18r12475.
     Google Scholar
  10. Khorramzadeh E, and Lofty A. The use of ketamine in psychiatry. Psychosomatics, 1973;14:344-346.
     Google Scholar
  11. Krupitsky E, Grinenko A, Berkaliev T, Paley A, Petrov V, Moshkov K, and Borodkin Y. The combination of psychedelic and aversive approaches in alcoholism treatment. Alcoholism Treatment Quarterly. 1992;9, 99-105.
     Google Scholar
  12. Krupitsky E, and Grinenko A. Ketamine Psychedelic Therapy (KPT): A review of the results of ten years of research. Journal of Psychoactive Drugs. 1997;29(2):165-183.
     Google Scholar
  13. Dore J, Turnipseed B, Dwyer S, Turnipseed A, Andries J, Ascani G, Monnette C, Huidekoper A, Strauss N, and Wolfson P. Ketamine assisted psychotherapy (KAP): Patient demographics, clinical data and outcomes in three large practices administering ketamine with psychotherapy. Journal of Psychoactive Drugs. 2019;51(2):189-198.
     Google Scholar
  14. Hasler G. Toward specific ways to combine ketamine and psychotherapy in treating depression CNS Spectrums. 2020;25(3):445-447. doi: 10.1017/S1092852919001007.
     Google Scholar
  15. Kolp E, Young SM, Freidman H, Krupitsky E, Jansen K, and O’Connor L. Ketamine-enhanced psychotherapy: Preliminary clinical observations on its effects in treating death anxiety. International Journal of Transpersonal Studies, 2007;26(1):1-17.
     Google Scholar
  16. http://dx.doi.org/10.24972/ijts.2007.26.1.1
     Google Scholar
  17. Zdyb T. Treatment Protocol for Psychedelic-Enhanced Psychotherapy: Therapeutic Reset of Internal Processes (TRIP) (publication forthcoming).
     Google Scholar
  18. Souery D, Amsterdam J, de Montigny C, Lecrubier Y, Montgomery S, Lipp O, Racagni G, Zohar J, Mendlewicz J. Treatment resistant depression: methodological overview and operational criteria. Europen Neuropsychopharmacology. 1999;9(1-2):83-91. doi: 10.1016/s0924-977x(98)00004-2.
     Google Scholar
  19. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. Journal of General Internal Medicine. 2001;16(9):606-613.
     Google Scholar